TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06156202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Rehabilitation
Description: Subjects will be given the option to undergo the comprehensive rehabilitation program including speech therapy and physical therapy. Progression through the rehabilitation program will be personalized and designed based on impairments identified during the comprehensive baseline assessment and previous sessions. Subjects will undergo 12 one- hour sessions over the course of six weeks. The exercise program will be graded and targeted to the person's physical capacity with the goal of slowly advancing the exercise duration or intensity to effect physiological strengthening and increased physical function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Augmented Usual Care
Description: Following randomization, subjects in the augmented usual care group will be given the results of their in-person baseline assessment as well as the WHO Guide Support for Rehabilitation Self-Management after COVID-19 Related Illness. This guide consists of ways to manage: breathlessness, difficulty with voice, eating, drinking and swallowing; problems with attention, memory and thinking clearly; limitations in activities of daily living, manage stress and mood dysfunction and advice for when to contact healthcare professionals. Follow-up interviews will assess process measures, including use of outpatient rehabilitation clinics, to examine possible contamination effects
Study: NCT06274112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: TMS will be administered using a Cool B-65 coil to a personalized right dlPFC region.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: TMS will be administered using a Cool B-65 coil to a personalized right dlPFC region.
Study: NCT06083142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation capsules
Description: Fecal microbiota transplantation capsules
Study: NCT05491213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TELESCOPE, Remote Decision Coaching with Navigation Intervention
Description: The TELESCOPE intervention involves three complementary components: 1) decision aid and coaching for LCS, 2) referral of current smokers to evidence-based smoking cessation services, and 3) for participants interested in screening, navigation to complete LCS and diagnostic testing and oncology care as needed
Study: NCT05702281

Intervention type: DEVICE
Group type: OTHER
Intervention: ReLARC
Description: ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.

Intervention type: DEVICE
Group type: OTHER
Intervention: ReLARC
Description: ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.
Study: NCT06188767

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone Undecanoate
Description: Following testosterone/placebo injection, participants undergo supervised resistance training for 4 weeks. This period is followed by a washout period with no drug and either continued resistance training or detraining for 16 weeks. Thereafter, another 4-week period with supervised resistance training is commenced, with no drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate
Description: Following testosterone/placebo injection, participants undergo supervised resistance training for 4 weeks. This period is followed by a washout period with no drug and either continued resistance training or detraining for 16 weeks. Thereafter, another 4-week period with supervised resistance training is commenced, with no drug.
Study: NCT06509386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder without treatment or role fulfillment
Description: Read vignette describing the condition and ask stigma questions.
Study: NCT06777745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Model-assisted breast examination application
Description: Designed for the development of self-examination skills, this model is in the shape of a female upper body with medium-sized breasts. Thanks to its ergonomic design, it can be worn easily and offers a comfortable use. Made of high quality, dermatologically tested and tactile silicone material. This model, which reflects all the details of the skin realistically, has a structure suitable for standing and lying examination. For educational use, there are 2 benign tumours, 4 malignant tumours and 2 typical anomalies. This model allows for practical explanation of all stages of breast examination such as determining the area to be examined, manual examination of the area, examination method, nipple examination and detection of malignant formations in the breast.
Study: NCT06779591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CareAide® Medication Adherence Mobile Application
Description: CareAide® app is one of the mobile apps in assisting and improving patients' adherence to medications. It is an unique health-tech and insure-tech company with expertise in behavioural science, chronic condition management and technology. The app aims to help patients with chronic conditions live a better everyday life and empower their families and the ecosystem around the patients to drive better outcomes. They have the clinically validated approach to improving adherence. Using behavioural science and smart tech, they improve the day-to-day life of patients, and importantly, empower both patients and health care providers with the digital tools and near real-time insights to proactively manage risks, intervene early to avoid patient emergencies and to help to provide a better customer satisfaction.
Study: NCT06779344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MxA and CRP tests
Description: A whole blood sample will be collected on the day of randomization for MxA and CRP testing.
Study: NCT06509386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder with treatment but no role fulfillment
Description: Read vignette describing the condition and ask stigma questions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder without treatment but with role fulfillment
Description: Read vignette describing the condition and ask stigma questions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder with treatment and role fulfillment
Description: Read vignette describing the condition and ask stigma questions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schizophrenia without treatment or role fulfillment
Description: Read vignette describing the condition and ask stigma questions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schizophrenia with treatment but no role fulfillment
Description: Read vignette describing the condition and ask stigma questions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schizophrenia without treatment but with role fulfillment
Description: Read vignette describing the condition and ask stigma questions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schizophrenia with treatment and role fulfillment
Description: Read vignette describing the condition and ask stigma questions.
Study: NCT06453213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: The 100 mg/ day Treatment Period includes a 6-week Titration Phase and a 26-week Maintenance Phase. During the Titration Phase subjects will be treated with cenobamate 12.5 mg/day for two weeks, 25 mg/day for two weeks and 50 mg/day for two weeks. Subjects tolerating cenobamate at the end of the Titration Phase will continue treatment with 100 mg/day in the Maintenance Phase for 26 weeks. If the subject does not experience a seizure in the 100 mg/day Maintenance Phase, he/she can enter the Optional Extension Period (100 mg/day).~The 200 mg/day treatment period consists of a 2-week Titration Phase and a 26-week Maintenance Phase. During the 2-week Titration Phase, subjects will receive cenobamate 150 mg/day before entering the 26-week 200 mg/day Maintenance Phase. If the subject does not experience a seizure during the 200 mg/day Maintenance Phase, he/she can enter the 26 week Optional Extension Period (200 mg/day).
Study: NCT05966636

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fractional CO2 Laser Ablative Resurfacing
Description: Fractional lasers stimulate scar improvement through production of microscopic patterns of dermal injury, vaporizing scar tissue and inducing neocollagenesis, subsequently improving scar tissue texture and range of motion, and decreasing symptoms such as pain and pruritis. Current clinical consensus is supportive that fractionated lasers are the most effective option for the treatment of scars. Other laser wavelengths and modalities used for vascular deformities and hair removal for instance, have an adjunctive role in improving scars and may be used in the same laser session. Case reports provide evidence of substantial improvement in sensory symptoms and physical mobility within days to weeks after each treatment.
Study: NCT06428019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral: Tablet
Study: NCT06073912

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mineralized plasmatic matrix graft
Description: Simultaneous implant placement with sinus lifting and grafting using mineralized plasmatic matrix that is formed using PRP of the patient mixed with particulate autogenous graft from the chin area

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centrifuge
Description: Centrifuge will be needed to get the PRP in the Comparator group and PRP in both groups

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Centrifuge
Description: Centrifuge will be needed to get the PRP in the Comparator group and PRP in both groups

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACM bur
Description: Auto Chip Maker will be used to collect the autogenous particulate bone graft for the sticky bone graft
Study: NCT06428019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Oral: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Oral: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Oral: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous Infusion
Study: NCT05931302

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-46 PET scan
Description: 68Ga-FAPI-46 is a radiotracer for the detection of Fibroblast Activation Protein (FAP) in cancer patients.~68Ga-FAPI-46 will be administered intravenously at a dose of 2MBq/kg. Patients will be scanned 60 minutes after administration of 68Ga-FAPI-46.
Study: NCT06527365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VDPHL01
Description: VDPHL01 Extended Release (ER) Tablet
Study: NCT05999799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1070806
Description: GSK1070806 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1070806
Description: GSK1070806 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1070806
Description: GSK1070806 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1070806
Description: GSK1070806 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT04484818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Given via injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given via injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IV
Study: NCT05960266

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polvac Grass+Rye
Description: Aqueous suspension of a co-precipitate of allergen extract and tyrosine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polvac Grass+Rye
Description: Aqueous suspension of a co-precipitate of allergen extract and tyrosine
Study: NCT04910802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil9
Description: Concomitant vaccination and HPV screening. Gardasil9 will be administered using standard dosage. 1 dose at recruitment and the 2nd dose 3 years later.
Study: NCT04484818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Given via injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Given via injection
Study: NCT06512077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection
Description: Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
Study: NCT06165341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fazirsiran Injection
Description: Fazirsiran will be injected subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fazirsiran matching placebo.
Study: NCT04720209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CARE
Description: CARE is a 16-week, supervised, periodized AE and RE program performed in a circuit fashion 3 days/week on-site

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TARE
Description: TARE is a 16- week, supervised AE and RE program consisting of three sessions per week on-site

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Stretching
Description: This group will perform a home-based program of the same stretches utilized in the CARE and TARE groups.
Study: NCT05760131

Intervention type: OTHER
Intervention: Patient Participation Form
Description: A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
Study: NCT04678986

Intervention type: OTHER
Intervention: ER2
Description: No intervention, data analysis only
Study: NCT05382468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise
Description: Intradialytic exercise comprised of a set warm up, aerobic, active,passive \& cool down activities performed by patients during dialysis for a period of 30 min twice or thrice a week regularly for one month \& supervised by principle investigator.
Study: NCT05808946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-Lipoic Acid
Description: 1200 mg of ALA daily (given as two 600 mg capsules once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepsis Supportive Care
Description: Appropriate IV fluid, Appropriate antibiotic, Vasopressors if needed, Mechanical ventilation if needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sepsis Supportive Care
Description: Appropriate IV fluid, Appropriate antibiotic, Vasopressors if needed, Mechanical ventilation if needed
Study: NCT05011305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 2 mg
Description: Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 4 mg
Description: Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomly assigned to this group will receive Placebo tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
Study: NCT04609592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutathera
Description: 4 administrations of 7.4 gigabecquerel (GBq) (200 mCi) 177Lu Dotatate +/ 10% at the date and time of infusion, accumulative dose of 29.6 GBq (800 mCi). T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium 68 Dotatate
Description: Standard of care, 2 Megabecquerel (MBq)/kg (0.054 mCi/kg) up to 200 MBq (5.4 mCi)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Medical Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Medical Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Medical Imaging
Study: NCT05373784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual into the gastrointestinal tract of another individual. This is currently an accepted method of treatment for recurrent colitis secondary to Clostridium difficile infection refractory to antibiotics/medical management. FMT can be delivered via capsule endoscopy or via colonoscopy. In this study, it will be administered via colonoscopy.
Study: NCT05476497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLP Peanut
Description: solution for subcutaneous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLP Peanut
Description: solution for subcutaneous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: solution for subcutaneous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLP Peanut
Description: solution for Skin-prick testing
Study: NCT06394544

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brazil Nut
Description: The intervention, for each participant, is estimated to last a total period of six months , which will be divided into three two-month stages, with data collection after each stage. Volunteers will be monitored to control possible side effects, doubts and check compliance. In addition, the telephone number and an email will be made available for contact during business hours, for possible clarifications.
Study: NCT05817708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-4945
Description: Drug: CX-4945~Silmitasertib, orally, once or twice daily for 5 days.~Other Name: Silmitasertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-4945
Description: Drug: CX-4945~Silmitasertib, orally, once or twice daily for 5 days.~Other Name: Silmitasertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-4945
Description: Drug: CX-4945~Silmitasertib, orally, once or twice daily for 5 days.~Other Name: Silmitasertib
Study: NCT05854329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure
Description: Virtual Reality device using the immersive dental game.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Exposure
Description: Virtual Reality device using the immersive dental game.
Study: NCT05696392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib cream
Description: ruxolitinib cream 1.5% will be applied twice daily as a thin film
Study: NCT06784947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-Treatment Biopsy
Description: The pre-treatment biopsy should be performed at least 3 days prior to C1D1 of treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: On-Treatment Biopsy
Description: While the acceptable window for the C3D1 biopsy is ±3 days, it is preferred that the biopsy occurs following all treatments on C3D1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab is a human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. This treatment may help the immune system attack cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab is a human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. This treatment may help the immune system attack cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a type of targeted therapy drug called an immune checkpoint inhibitor. It is a monoclonal antibody that works by binding to the protein PD-L1 (programmed death) on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a type of targeted therapy drug called an immune checkpoint inhibitor. It is a monoclonal antibody that works by binding to the protein PD-L1 (programmed death) on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab works by blocking a protein called Vascular Endothelial Growth Factor (VEGF), which some cancer cells produce in large amounts. Blocking VEGF may prevent the growth of new blood vessels that tumors need to grow, and may help improve the immune response in the tumor. Bevacizumab is a type of targeted therapy called an angiogenesis inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab works by blocking a protein called Vascular Endothelial Growth Factor (VEGF), which some cancer cells produce in large amounts. Blocking VEGF may prevent the growth of new blood vessels that tumors need to grow, and may help improve the immune response in the tumor. Bevacizumab is a type of targeted therapy called an angiogenesis inhibitor.